全球基於人工智慧（AI）的重症監護市場－產業趨勢及2029年預測

Customize Your Report Customize Your Report 立即购买 立即购买 免费样本报告 免费样本报告
Home Medical Devices Global Ai Based Critical Care Market
请求目录 请求目录 与分析师交谈 与分析师交谈 免费样本报告 免费样本报告 购买前请咨询 提前咨询 立即购买 立即购买

全球基於人工智慧（AI）的重症監護市場－產業趨勢及2029年預測

  • Medical Devices
  • Upcoming Report
  • Aug 2022
  • Global
  • 350 页面
  • 桌子數： 220
  • 图号： 60
立即购买 立即购买 索取樣品 索取樣品
Nucleus Nucleus

通过敏捷供应链咨询解决关税挑战

供应链生态系统分析现已成为 DBMR 报告的一部分

Global Ai Based Critical Care Market

市场规模（十亿美元）

CAGR :  % Diagram

Chart Image USD 7.00 Billion USD 58.16 Billion 2021 2029
Diagram Forecast Period
 2022 –2029
Diagram Market Size (Base Year)
 USD 7.00 Billion
Diagram Market Size (Forecast Year)
 USD 58.16 Billion
Diagram CAGR
 %
Diagram Major Markets Players
  • Nvidia Corporation (U.S.)
  • IBM (U.S.)
  • AiCure (U.S.)
  • iCarbonX (China)
  • Cyrcadia Health Inc. (U.S.)

全球基於人工智慧 (AI) 的重症監護市場，透過提供（硬體、軟體、服務）、技術（機器學習、情境感知計算、自然語言處理、電腦視覺、語音識別、查詢方法）、應用（健康監測、數位諮詢、虛擬護理師、精準醫療、藥物創造、醫療保健系統分析、藥物管理等）——行業趨勢和預測到 2029 年。

全球基於人工智慧（AI）的重症監護市場

全球基於人工智慧（AI）的重症監護市場分析和規模

預計基於人工智慧 (AI) 的重症監護市場將在預測期內實現顯著成長。在醫療保健產業，人工智慧被用於研究治療方法與患者預後之間的關係。人工智慧在藥物研究、治療方案和藥物管理方面有著廣泛的應用，例如診斷、客製化用藥、藥物研發和病患照護監測等醫療程序。醫療保健領域對人工智慧的需求主要源自於醫療市場的成長以及資料集的複雜性和大量資料。

數據橋市場研究公司 (Data Bridge Market Research) 分析了 2022-2029 年預測期內基於人工智慧 (AI) 的重症監護市場的成長率。在上述預測期內，基於人工智慧 (AI) 的重症監護市場的預期複合年增長率約為 30.30%。 2021 年，該市場價值為 70 億美元，到 2029 年將成長至 581.6 億美元。除了市場價值、成長率、細分市場、地理覆蓋範圍、市場參與者和市場情景等市場洞察外，數據橋市場研究團隊整理的市場報告還包含深入的專家分析、患者流行病學、產品線分析、定價分析和監管框架。

市場定義

人工智慧被定義為一種智慧系統，它運用生物學、電腦科學、數學、語言學、心理學和工程學等領域的眾多基於人類智慧的功能。這些功能包括推理、學習和解決問題的能力。醫療產業的人工智慧使用演算法和軟體來評估複雜的醫療數據。

全球基於人工智慧（AI）的重症監護市場範圍和細分

報告指標

細節

預測期

2022年至2029年

基準年

2021

歷史歲月

2020（可自訂為 2014 - 2019）

定量單位

收入（十億美元）、銷售（單位）、定價（美元）

涵蓋的領域

按產品（硬體、軟體、服務）、技術（機器學習、情境感知計算、自然語言處理、電腦視覺、語音辨識、查詢方法）、應用（健康監測、數位諮詢、虛擬護理師、精準醫療、藥物研發、醫療保健系統分析、藥物管理等）

覆蓋國家

北美洲的美國、加拿大和墨西哥、德國、法國、英國、荷蘭、瑞士、比利時、俄羅斯、義大利、西班牙、土耳其、歐洲其他地區、中國、日本、印度、韓國、新加坡、馬來西亞、澳洲、泰國、印尼、菲律賓、亞太地區 (APAC) 的其他地區、沙烏地阿拉伯、阿聯酋、南非、埃及、以色列、中東和非洲 (MEA) 的其他地區、其他地區的歐洲地區

涵蓋的市場參與者

Nvidia Corporation（美國）、IBM（美國）、AiCure（美國）、iCarbonX（中國）、Cyrcadia Health Inc.（美國）、Atomwise, Inc.（美國）、Pathway（美國）、SOPHiA GENETICS（瑞士）、Apixio, Inc.（美國）、General Vision）

市場機會
  • 最新動態
  • 輔助臨床研究

全球基於人工智慧（AI）的重症監護市場動態

驅動程式

  • 新創新技術的出現

有助於提高人工智慧軟體效率和效能的先進硬體系統的出現，預計將推動硬體領域的市場成長。例如，2016年，英偉達提高了深度學習的效率，並推出了比CPU效率高20到50倍的GPU。

  • 政府舉措

政府支持的舉措、私人投資者和風險資本家增加的投資以及世界各地專注於人工智慧的新創企業的出現正在推動市場成長。

機會

  • 最新動態

基於人工智慧的技術在接受度和發展速度方面都取得了顯著成長。隨著最新進展的推進，對這些基於人工智慧技術的需求也日益增長。例如，2017 年 8 月，賓州大學醫學院開發了一種基於機器學習的預測解決方案。在這個解決方案中，該系統可以幫助分析患者的生命體徵，預測敗血症的風險，並識別心臟衰竭的可能性。

  • 輔助臨床研究

基於人工智慧的臨床試驗技術正在迅速普及。預計該技術將透過縮短臨床試驗時間並提高臨床試驗的準確性和可靠性來促進市場成長。這有望在預測期內推動染色質免疫沉澱定序市場的發展。

限制/挑戰

  • 缺乏熟練的專業人員

缺乏能夠使用這些人工智慧技術的合格人員可能會在預測期內抑制全球基於人工智慧的重症監護市場的成長。

  • 高成本

儘管這些疾病的盛行率很高，但這些技術的高成本可能會阻礙全球基於人工智慧的重症監護市場的成長。

這份基於人工智慧 (AI) 的重症監護市場報告詳細介紹了最新發展動態、貿易法規、進出口分析、生產分析、價值鏈優化、市場份額、國內和本地市場參與者的影響，並分析了新興收入來源、市場法規變化、戰略市場增長分析、市場規模、品類市場增長、應用領域和市場主導地位、產品擴展、產品發布、戰略市場增長分析以及市場發布、品類市場增長、應用領域和市場主導地位、產品擴展、產品發布、戰略市場增長分析以及市場發布和市場創新領域的創新領域。如需了解更多關於基於人工智慧 (AI) 的重症監護市場的信息，請聯繫 Data Bridge 市場研究部門獲取分析師簡報，我們的團隊將幫助您做出明智的市場決策，實現市場成長。

COVID-19 對全球基於人工智慧（AI）的重症監護市場的影響

就目前情勢而言，新冠疫情已造成一場前所未有的全球公共衛生危機，幾乎影響了所有企業。其長期影響預計將在預測期內影響產業成長。

人工智慧技術的採用受到醫療保健提供者日益增長的需求、降低醫療保健成本上升的需求、基於價值的護理的需求以及準確、快速地診斷和檢測潛在健康狀況以便盡快提供最佳治療方案的日益增長的需求的推動。

全球基於人工智慧（AI）的重症監護市場範圍

基於人工智慧 (AI) 的重症監護市場根據產品、技術和應用進行細分。這些細分市場的成長將有助於您分析行業中成長乏力的細分市場，並為用戶提供有價值的市場概覽和市場洞察，幫助他們做出策略決策，從而確定核心市場應用。

奉獻

  • 硬體
  • 軟體
  • 服務

科技

  • 機器學習
  • 情境感知計算
  • 自然語言處理
  • 電腦視覺
  • 語音辨識
  • 查詢方式

應用

  • 健康監測
  • 數位諮詢
  • 虛擬護理師
  • 精準醫療
  • 藥物研發
  • 醫療保健系統分析
  • 藥物管理
  • 其他的

基於人工智慧（AI）的重症監護市場區域分析/洞察

對基於人工智慧 (AI) 的重症監護市場進行了分析，並透過上述產品、技術和應用提供了市場規模洞察和趨勢。

基於美國、加拿大和墨西哥 (AI) 的重症監護市場報告涵蓋的主要國家 有：北美的美國、加拿大和墨西哥、歐洲的德國、法國、英國、荷蘭、瑞士、比利時、俄羅斯、義大利、西班牙、土耳其、歐洲其他地區、中國、日本、印度、韓國、新加坡、馬來西亞、澳洲、泰國、印尼、菲律賓、亞太地區 (APAC) 的其他地區、阿拉伯的其他地區、南美洲的巴西、阿根廷和南美洲其他地區。

由於醫療保健 IT 基礎設施的進步、醫療支出的不斷增長、技術的廣泛採用、政府的有利舉措以及幾個主要市場參與者的存在，北美成為主導市場。

預計亞太地區將因 IT 基礎設施和專注於人工智慧技術的創業企業的快速創新和發展而實現成長。

報告的國家部分還提供了各個市場的影響因素以及國內市場監管變化，這些變化會影響市場的當前和未來趨勢。此外，報告還考慮了全球品牌的存在和可用性，以及它們因本土和國內品牌的激烈競爭或稀缺而面臨的挑戰，以及國內關稅和貿易路線的影響，並對各國數據進行了預測分析。

競爭格局和基於人工智慧（AI）的全球重症監護市場份額分析

基於人工智慧 (AI) 的重症監護市場競爭格局提供了按競爭對手劃分的詳細資訊。詳細資訊包括公司概況、公司財務狀況、收入、市場潛力、研發投入、新市場計劃、全球佈局、生產基地和設施、生產能力、公司優勢和劣勢、產品發布、產品寬度和廣度以及應用主導地位。以上提供的數據僅與公司在基於人工智慧 (AI) 的重症監護市場的重點相關。

基於人工智慧（AI）的重症監護市場的主要參與者包括：

  • Nvidia公司（美國）
  • IBM（美國）
  • AiCure（美國）
  • 碳雲智能（中國）
  • Cyrcadia Health Inc.（美國）
  • Atomwise, Inc.（美國）
  • 途徑（美國）
  • 索菲亞遺傳學（瑞士）
  • Apixio, Inc.（美國）
  • General Vision, Inc.（美國）
  • 微軟（美國）
  • 英特爾公司（美國）
  • DeepMind Technologies Limited（英國）

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

Sample Image Click on image to enlarge
  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL ARTIFICIAL INTELLIGENCE (AI) BASED CRITICAL CARE MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL ARTIFICIAL INTELLIGENCE (AI) BASED CRITICAL CARE MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 MARKET GUIDE

2.2.4 COMPANY POSITIONING GRID

2.2.5 COMPANY MARKET SHARE ANALYSIS

2.2.6 MULTIVARIATE MODELLING

2.2.7 TOP TO BOTTOM ANALYSIS

2.2.8 STANDARDS OF MEASUREMENT

2.2.9 VENDOR SHARE ANALYSIS

2.2.10 SALES VOLUME

2.2.11 EPIDEMIOLOGY MODELLING

2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL ARTIFICIAL INTELLIGENCE (AI) BASED CRITICAL CARE MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 CHALLENGES

4 EXECUTIVE SUMMARY

 

5 PREMIUM INSIGHTS

5.1 PESTAL ANALYSIS

5.2 PORTER’S FIVE FORCES

5.3 KEY STRATEGIC INITIATIVES

6 GLOBAL ARTIFICIAL INTELLIGENCE (AI) BASED CRITICAL CARE MARKET, BY OFFERING

6.1 OVERVIEW

6.2 HARDWARE

6.2.1 VENTILATORS

6.2.1.1. MARKET VALUE (USD MILLION)

6.2.1.2. MARKET VOLUME (UNITS)

6.2.1.3. AVERAGE SELLING PRICE (USD)

6.2.2 DRUG MANAGEMENT SYSTEM

6.2.2.1. MARKET VALUE (USD MILLION)

6.2.2.2. MARKET VOLUME (UNITS)

6.2.2.3. AVERAGE SELLING PRICE (USD)

6.2.3 VITAL MONITORING SYSTEM

6.2.3.1. MARKET VALUE (USD MILLION)

6.2.3.2. MARKET VOLUME (UNITS)

6.2.3.3. AVERAGE SELLING PRICE (USD)

6.2.4 INFUSION PUMPS

6.2.4.1. MARKET VALUE (USD MILLION)

6.2.4.2. MARKET VOLUME (UNITS)

6.2.4.3. AVERAGE SELLING PRICE (USD)

6.2.5 ECG DEVICES

6.2.5.1. MARKET VALUE (USD MILLION)

6.2.5.2. MARKET VOLUME (UNITS)

6.2.5.3. AVERAGE SELLING PRICE (USD)

6.2.6 OTHERS

6.3 SOFTWARE

6.3.1 DATA AGGREGATION

6.3.2 DATA INTEGRATION

6.3.3 DATA ANALYTICS

6.3.3.1. DATA COLLECTION

6.3.3.2. DATA ACCESS

6.3.3.3. DATA WAREHOUSING

6.3.3.4. DATA MINING

6.3.4 DATA VISUALIZATION

6.3.5 OTHERS

 

6.4 SERVICES

6.4.1 BY SERVICE TYPE

6.4.1.1. TELE-CONSULATATION

6.4.1.1.1. CENTRALIZED TELE-ICU

6.4.1.1.2. DECENTRALIZED TELE-ICUHYBRID TELE-ICU

6.4.1.2. CRITICAL-CARE NURSING

6.4.1.3. HEALTH ATTENDANT

6.4.1.4. PATIENT VITAL MONITORING SUPPORT

6.4.1.5. OTHERS

6.4.2 BY DISEASE TYPE

6.4.2.1. NEUROLOGY

6.4.2.2. CANCER (INCLUDING PALLIATIVE CARE)

6.4.2.3. PULMONOLOGY

6.4.2.4. CARDIAC

6.4.2.5. NEPHROLOGY

6.4.2.6. OTHERS

6.5 OTHERS

7 GLOBAL ARTIFICIAL INTELLIGENCE (AI) BASED CRITICAL CARE MARKET, BY TECHNOLOGY

7.1 OVERVIEW

7.2 MACHINE LEARNING

7.3 CONTEXT-AWARE COMPUTING

7.4 NATURAL LANGUAGE PROCESSING

7.5 COMPUTER VISION

7.6 SPEECH RECOGNITION

7.7 QUERYING METHOD

8 GLOBAL ARTIFICIAL INTELLIGENCE (AI) BASED CRITICAL CARE MARKET, BY APPLICATION

8.1 OVERVIEW

8.2 HEALTH MONITORING

8.2.1 HARDWARE

8.2.2 SOFTWARE

8.2.3 SERVICES

8.3 DIGITAL CONSULTATION

8.3.1 HARDWARE

8.3.2 SOFTWARE

8.3.3 SERVICES

 

8.4 VIRTUAL NURSES

8.4.1 HARDWARE

8.4.2 SOFTWARE

8.4.3 SERVICES

8.5 PRECISION MEDICINE

8.5.1 HARDWARE

8.5.2 SOFTWARE

8.5.3 SERVICES

8.6 DRUG CREATION

8.6.1 HARDWARE

8.6.2 SOFTWARE

8.6.3 SERVICES

8.7 HEALTHCARE SYSTEM ANALYSIS

8.7.1 HARDWARE

8.7.2 SOFTWARE

8.7.3 SERVICES

8.8 MEDICATION MANAGEMENT

8.8.1 HARDWARE

8.8.2 SOFTWARE

8.8.3 SERVICES

8.9 OTHERS

9 GLOBAL ARTIFICIAL INTELLIGENCE (AI) BASED CRITICAL CARE MARKET, BY END USER

9.1 OVERVIEW

9.2 HOSPITALS

9.3 AMBULATORY SURGICAL CENTERS

9.4 SPECIALTY CLINICS

9.5 OTHERS

10 GLOBAL ARTIFICIAL INTELLIGENCE (AI) BASED CRITICAL CARE MARKET, BY DISTRIBUTION CHANNEL

10.1 OVERVIEW

10.2 DIRECT TENDER

10.3 THIRD PARTY DISTRIBUTORS

10.4 OTHERS

 

11 GLOBAL ARTIFICIAL INTELLIGENCE (AI) BASED CRITICAL CARE MARKET, BY REGION

GLOBAL ARTIFICIAL INTELLIGENCE (AI) BASED CRITICAL CARE MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

11.1 NORTH AMERICA

11.1.1 U.S.

11.1.1.1. U.S. ARTIFICIAL INTELLIGENCE (AI) BASED CRITICAL CARE MARKET, BY OFFERING

11.1.1.2. U.S. ARTIFICIAL INTELLIGENCE (AI) BASED CRITICAL CARE MARKET, BY TECHNOLOGY

11.1.1.3. U.S. ARTIFICIAL INTELLIGENCE (AI) BASED CRITICAL CARE MARKET, BY APPLICATION

11.1.1.4. U.S. ARTIFICIAL INTELLIGENCE (AI) BASED CRITICAL CARE MARKET, BY END USER

11.1.1.5. U.S. ARTIFICIAL INTELLIGENCE (AI) BASED CRITICAL CARE MARKET, BY DISTRIBUTION CHANNEL

11.1.2 CANADA

11.1.3 MEXICO

11.2 EUROPE

11.2.1 GERMANY

11.2.2 FRANCE

11.2.3 U.K.

11.2.4 ITALY

11.2.5 SPAIN

11.2.6 RUSSIA

11.2.7 TURKEY

11.2.8 BELGIUM

11.2.9 DENMARK

11.2.10 NETHERLANDS

11.2.11 SWITZERLAND

11.2.12 SWEDEN

11.2.13 POLAND

11.2.14 NORWAY

11.2.15 FINLAND

11.2.16 REST OF EUROPE

 

11.3 ASIA-PACIFIC

11.3.1 JAPAN

11.3.2 CHINA

11.3.3 SOUTH KOREA

11.3.4 INDIA

11.3.5 AUSTRALIA

11.3.6 NEW ZEALAND

11.3.7 SINGAPORE

11.3.8 THAILAND

11.3.9 MALAYSIA

11.3.10 VIETNAM

11.3.11 TAIWAN

11.3.12 INDONESIA

11.3.13 PHILIPPINES

11.3.14 REST OF ASIA-PACIFIC

11.4 SOUTH AMERICA

11.4.1 BRAZIL

11.4.2 ARGENTINA

11.4.3 REST OF SOUTH AMERICA

11.5 MIDDLE EAST AND AFRICA

11.5.1 SOUTH AFRICA

11.5.2 SAUDI ARABIA

11.5.3 BAHRAIN

11.5.4 UAE

11.5.5 KUWAIT

11.5.6 OMAN

11.5.7 QATAR

11.5.8 EGYPT

11.5.9 ISRAEL

11.5.10 REST OF MIDDLE EAST AND AFRICA

11.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

12 GLOBAL ARTIFICIAL INTELLIGENCE (AI) BASED CRITICAL CARE MARKET, SWOT AND DBMR ANALYSIS

 

13 GLOBAL ARTIFICIAL INTELLIGENCE (AI) BASED CRITICAL CARE MARKET, COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: GLOBAL

13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

13.3 COMPANY SHARE ANALYSIS: EUROPE

13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

13.5 MERGERS & ACQUISITIONS

13.6 NEW PRODUCT DEVELOPMENT & APPROVALS

13.7 EXPANSIONS

13.8 REGULATORY CHANGES

13.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

14 GLOBAL ARTIFICIAL INTELLIGENCE (AI) BASED CRITICAL CARE MARKET, COMPANY PROFILE

14.1 AUTONOMOUS HEALTHCARE

14.1.1 COMPANY OVERVIEW

14.1.2 REVENUE ANALYSIS

14.1.3 GEOGRAPHIC PRESENCE

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENTS

14.2 TORADEX SYSTEMS (INDIA) PVT. LTD.

14.2.1 COMPANY OVERVIEW

14.2.2 REVENUE ANALYSIS

14.2.3 GEOGRAPHIC PRESENCE

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENTS

14.3 BAXTER

14.3.1 COMPANY OVERVIEW

14.3.2 REVENUE ANALYSIS

14.3.3 GEOGRAPHIC PRESENCE

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENTS

14.4 WELLUE

14.4.1 COMPANY OVERVIEW

14.4.2 REVENUE ANALYSIS

14.4.3 GEOGRAPHIC PRESENCE

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENTS

 

14.5 ANUMANA, INC.

14.5.1 COMPANY OVERVIEW

14.5.2 REVENUE ANALYSIS

14.5.3 GEOGRAPHIC PRESENCE

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENTS

14.6 XORESEARCH

14.6.1 COMPANY OVERVIEW

14.6.2 REVENUE ANALYSIS

14.6.3 GEOGRAPHIC PRESENCE

14.6.4 PRODUCT PORTFOLIO

14.6.5 RECENT DEVELOPMENTS

14.7 ALIVECOR, INC.

14.7.1 COMPANY OVERVIEW

14.7.2 REVENUE ANALYSIS

14.7.3 GEOGRAPHIC PRESENCE

14.7.4 PRODUCT PORTFOLIO

14.7.5 RECENT DEVELOPMENTS

14.8 LEPU MEDICAL

14.8.1 COMPANY OVERVIEW

14.8.2 REVENUE ANALYSIS

14.8.3 GEOGRAPHIC PRESENCE

14.8.4 PRODUCT PORTFOLIO

14.8.5 RECENT DEVELOPMENTS

14.9 ETIOMETRY, INC.

14.9.1 COMPANY OVERVIEW

14.9.2 REVENUE ANALYSIS

14.9.3 GEOGRAPHIC PRESENCE

14.9.4 PRODUCT PORTFOLIO

14.9.5 RECENT DEVELOPMENTS

14.1 NETEERA

14.10.1 COMPANY OVERVIEW

14.10.2 REVENUE ANALYSIS

14.10.3 GEOGRAPHIC PRESENCE

14.10.4 PRODUCT PORTFOLIO

14.10.5 RECENT DEVELOPMENTS

 

14.11 VITLS

14.11.1 COMPANY OVERVIEW

14.11.2 REVENUE ANALYSIS

14.11.3 GEOGRAPHIC PRESENCE

14.11.4 PRODUCT PORTFOLIO

14.11.5 RECENT DEVELOPMENTS

14.12 APOLLO TELEHEALTH

14.12.1 COMPANY OVERVIEW

14.12.2 REVENUE ANALYSIS

14.12.3 GEOGRAPHIC PRESENCE

14.12.4 PRODUCT PORTFOLIO

14.12.5 RECENT DEVELOPMENTS

14.13 EAGLE TELEMEDICINE

14.13.1 COMPANY OVERVIEW

14.13.2 REVENUE ANALYSIS

14.13.3 GEOGRAPHIC PRESENCE

14.13.4 PRODUCT PORTFOLIO

14.13.5 RECENT DEVELOPMENTS

14.14 GE HEALTHCARE

14.14.1 COMPANY OVERVIEW

14.14.2 REVENUE ANALYSIS

14.14.3 GEOGRAPHIC PRESENCE

14.14.4 PRODUCT PORTFOLIO

14.14.5 RECENT DEVELOPMENTS

14.15 HICUITY HEALTH

14.15.1 COMPANY OVERVIEW

14.15.2 REVENUE ANALYSIS

14.15.3 GEOGRAPHIC PRESENCE

14.15.4 PRODUCT PORTFOLIO

14.15.5 RECENT DEVELOPMENTS

14.16 INTERCEPT TELEMED

14.16.1 COMPANY OVERVIEW

14.16.2 REVENUE ANALYSIS

14.16.3 GEOGRAPHIC PRESENCE

14.16.4 PRODUCT PORTFOLIO

14.16.5 RECENT DEVELOPMENTS

 

14.17 KONINKLIJKE PHILIPS

14.17.1 COMPANY OVERVIEW

14.17.2 REVENUE ANALYSIS

14.17.3 GEOGRAPHIC PRESENCE

14.17.4 PRODUCT PORTFOLIO

14.17.5 RECENT DEVELOPMENTS

14.18 SOC TELEMED

14.18.1 COMPANY OVERVIEW

14.18.2 REVENUE ANALYSIS

14.18.3 GEOGRAPHIC PRESENCE

14.18.4 PRODUCT PORTFOLIO

14.18.5 RECENT DEVELOPMENTS

14.19 TELADOC HEALTH

14.19.1 COMPANY OVERVIEW

14.19.2 REVENUE ANALYSIS

14.19.3 GEOGRAPHIC PRESENCE

14.19.4 PRODUCT PORTFOLIO

14.19.5 RECENT DEVELOPMENTS

14.2 AVEL ECARE

14.20.1 COMPANY OVERVIEW

14.20.2 REVENUE ANALYSIS

14.20.3 GEOGRAPHIC PRESENCE

14.20.4 PRODUCT PORTFOLIO

14.20.5 RECENT DEVELOPMENTS

14.21 CEIBA HEALTH

14.21.1 COMPANY OVERVIEW

14.21.2 REVENUE ANALYSIS

14.21.3 GEOGRAPHIC PRESENCE

14.21.4 PRODUCT PORTFOLIO

14.21.5 RECENT DEVELOPMENTS

14.22 CLEW

14.22.1 COMPANY OVERVIEW

14.22.2 REVENUE ANALYSIS

14.22.3 GEOGRAPHIC PRESENCE

14.22.4 PRODUCT PORTFOLIO

14.22.5 RECENT DEVELOPMENTS

 

14.23 CLOUDPHYSICIAN

14.23.1 COMPANY OVERVIEW

14.23.2 REVENUE ANALYSIS

14.23.3 GEOGRAPHIC PRESENCE

14.23.4 PRODUCT PORTFOLIO

14.23.5 RECENT DEVELOPMENTS

14.24 CRITINEXT

14.24.1 COMPANY OVERVIEW

14.24.2 REVENUE ANALYSIS

14.24.3 GEOGRAPHIC PRESENCE

14.24.4 PRODUCT PORTFOLIO

14.24.5 RECENT DEVELOPMENTS

14.25 IMDSOFT

14.25.1 COMPANY OVERVIEW

14.25.2 REVENUE ANALYSIS

14.25.3 GEOGRAPHIC PRESENCE

14.25.4 PRODUCT PORTFOLIO

14.25.5 RECENT DEVELOPMENTS

14.26 REMOTEICU

14.26.1 COMPANY OVERVIEW

14.26.2 REVENUE ANALYSIS

14.26.3 GEOGRAPHIC PRESENCE

14.26.4 PRODUCT PORTFOLIO

14.26.5 RECENT DEVELOPMENTS

14.27 SRI LAXMI KRAVIA TECHLABS

14.27.1 COMPANY OVERVIEW

14.27.2 REVENUE ANALYSIS

14.27.3 GEOGRAPHIC PRESENCE

14.27.4 PRODUCT PORTFOLIO

14.27.5 RECENT DEVELOPMENTS

14.28 VEEONE HEALTH

14.28.1 COMPANY OVERVIEW

14.28.2 REVENUE ANALYSIS

14.28.3 GEOGRAPHIC PRESENCE

14.28.4 PRODUCT PORTFOLIO

14.28.5 RECENT DEVELOPMENTS

 

14.29 ENEXT ICU

14.29.1 COMPANY OVERVIEW

14.29.2 REVENUE ANALYSIS

14.29.3 GEOGRAPHIC PRESENCE

14.29.4 PRODUCT PORTFOLIO

14.29.5 RECENT DEVELOPMENTS

14.3 INOVA

14.30.1 COMPANY OVERVIEW

14.30.2 REVENUE ANALYSIS

14.30.3 GEOGRAPHIC PRESENCE

14.30.4 PRODUCT PORTFOLIO

14.30.5 RECENT DEVELOPMENTS

14.31 T-ICU

14.31.1 COMPANY OVERVIEW

14.31.2 REVENUE ANALYSIS

14.31.3 GEOGRAPHIC PRESENCE

14.31.4 PRODUCT PORTFOLIO

14.31.5 RECENT DEVELOPMENTS

14.32 GENERAL VISION INC.

14.32.1 COMPANY OVERVIEW

14.32.2 REVENUE ANALYSIS

14.32.3 GEOGRAPHIC PRESENCE

14.32.4 PRODUCT PORTFOLIO

14.32.5 RECENT DEVELOPMENTS

14.33 NVIDIA CORPORATION

14.33.1 COMPANY OVERVIEW

14.33.2 REVENUE ANALYSIS

14.33.3 GEOGRAPHIC PRESENCE

14.33.4 PRODUCT PORTFOLIO

14.33.5 RECENT DEVELOPMENTS

14.34 IBM CORPORATION

14.34.1 COMPANY OVERVIEW

14.34.2 REVENUE ANALYSIS

14.34.3 GEOGRAPHIC PRESENCE

14.34.4 PRODUCT PORTFOLIO

14.34.5 RECENT DEVELOPMENTS

 

14.35 AICURE

14.35.1 COMPANY OVERVIEW

14.35.2 REVENUE ANALYSIS

14.35.3 GEOGRAPHIC PRESENCE

14.35.4 PRODUCT PORTFOLIO

14.35.5 RECENT DEVELOPMENTS

14.36 ICARBONX

14.36.1 COMPANY OVERVIEW

14.36.2 REVENUE ANALYSIS

14.36.3 GEOGRAPHIC PRESENCE

14.36.4 PRODUCT PORTFOLIO

14.36.5 RECENT DEVELOPMENTS

14.37 CYRCADIA HEALTH INC.

14.37.1 COMPANY OVERVIEW

14.37.2 REVENUE ANALYSIS

14.37.3 GEOGRAPHIC PRESENCE

14.37.4 PRODUCT PORTFOLIO

14.37.5 RECENT DEVELOPMENTS

14.38 ATOMWISE, INC.

14.38.1 COMPANY OVERVIEW

14.38.2 REVENUE ANALYSIS

14.38.3 GEOGRAPHIC PRESENCE

14.38.4 PRODUCT PORTFOLIO

14.38.5 RECENT DEVELOPMENTS

14.39 PATHWAY GENOMICS CORPORATION

14.39.1 COMPANY OVERVIEW

14.39.2 REVENUE ANALYSIS

14.39.3 GEOGRAPHIC PRESENCE

14.39.4 PRODUCT PORTFOLIO

14.39.5 RECENT DEVELOPMENTS

14.4 ZEBRA MEDICAL VISION LTD.

14.40.1 COMPANY OVERVIEW

14.40.2 REVENUE ANALYSIS

14.40.3 GEOGRAPHIC PRESENCE

14.40.4 PRODUCT PORTFOLIO

14.40.5 RECENT DEVELOPMENTS

 

14.41 SOPHIA GENETICS

14.41.1 COMPANY OVERVIEW

14.41.2 REVENUE ANALYSIS

14.41.3 GEOGRAPHIC PRESENCE

14.41.4 PRODUCT PORTFOLIO

14.41.5 RECENT DEVELOPMENTS

14.42 APIXIO INC.

14.42.1 COMPANY OVERVIEW

14.42.2 REVENUE ANALYSIS

14.42.3 GEOGRAPHIC PRESENCE

14.42.4 PRODUCT PORTFOLIO

14.42.5 RECENT DEVELOPMENTS

14.43 MICROSOFT

14.43.1 COMPANY OVERVIEW

14.43.2 REVENUE ANALYSIS

14.43.3 GEOGRAPHIC PRESENCE

14.43.4 PRODUCT PORTFOLIO

14.43.5 RECENT DEVELOPMENTS

14.44 INTEL CORPORATION

14.44.1 COMPANY OVERVIEW

14.44.2 REVENUE ANALYSIS

14.44.3 GEOGRAPHIC PRESENCE

14.44.4 PRODUCT PORTFOLIO

14.44.5 RECENT DEVELOPMENTS

14.45 DEEPMIND TECHNOLOGIES LIMITED

14.45.1 COMPANY OVERVIEW

14.45.2 REVENUE ANALYSIS

14.45.3 GEOGRAPHIC PRESENCE

14.45.4 PRODUCT PORTFOLIO

14.45.5 RECENT DEVELOPMENTS

14.46 VIZ.AI, INC.

14.46.1 COMPANY OVERVIEW

14.46.2 REVENUE ANALYSIS

14.46.3 GEOGRAPHIC PRESENCE

14.46.4 PRODUCT PORTFOLIO

14.46.5 RECENT DEVELOPMENTS

 

14.47 SUBTLE MEDICAL, INC.

14.47.1 COMPANY OVERVIEW

14.47.2 REVENUE ANALYSIS

14.47.3 GEOGRAPHIC PRESENCE

14.47.4 PRODUCT PORTFOLIO

14.47.5 RECENT DEVELOPMENTS

14.48 CLOUDMEDX INC.

14.48.1 COMPANY OVERVIEW

14.48.2 REVENUE ANALYSIS

14.48.3 GEOGRAPHIC PRESENCE

14.48.4 PRODUCT PORTFOLIO

14.48.5 RECENT DEVELOPMENTS

NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST

15 RELATED REPORTS

16 QUESTIONNAIRE

17 CONCLUSION

18 ABOUT DATA BRIDGE MARKET RESEARCH

查看详细信息 Right Arrow

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。

DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。

Frequently Asked Questions

市场是基于 全球基於人工智慧 (AI) 的重症監護市場，透過提供（硬體、軟體、服務）、技術（機器學習、情境感知計算、自然語言處理、電腦視覺、語音識別、查詢方法）、應用（健康監測、數位諮詢、虛擬護理師、精準醫療、藥物創造、醫療保健系統分析、藥物管理等）——行業趨勢和預測到 2029 年。 进行细分的。
在2021年，全球基於人工智慧（AI）的重症監護市場的规模估计为7.00 USD Billion美元。
全球基於人工智慧（AI）的重症監護市場预计将在2022年至2029年的预测期内以CAGR 30.3%的速度增长。
市场上的主要参与者包括Nvidia Corporation (U.S.), IBM (U.S.), AiCure (U.S.), iCarbonX (China), Cyrcadia Health Inc. (U.S.), Atomwise, Inc. (U.S.), Pathway (U.S.)., SOPHiA GENETICS (Switzerland), Apixio, Inc. (U.S.), General Vision, Inc.(U.S.), Microsoft (U.S.), Intel Corporation (U.S.), DeepMind Technologies Limited (U.K.)。

浏览相关页面

Banner
Testimonial
Image
David Manning - Thermo Fisher Scientific Director, Global Strategic Accounts,
Dear Ricky, I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.
Image
Manager - Market Analytics, Uriah D. Avila - Zeus Polymer Solutions
Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.
Image
Business Development Manager, (Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC
DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.
Image
Business Intelligence and Analytics, Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Image
Competition Analyst, Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Image
Marketing Director, Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

Image
COO, A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Image
Marketing Director, Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Image
Product manager, Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Image
Investor relations, GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Image
Market Analyst, Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Image
Andrew - Senior Global Marketing Manager, Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Image
Amarildo - Manager, Global Strategic Alignment MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Image
Tor Hammer Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Image
Tommaso Finocchiaro Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Image
Yuki Kopyl (Asian Business Development Department) UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future